Introduction {#jcmm13295-sec-0001}
============

As the most prevalent joint disease in developed countries, osteoarthritis (OA) has an immense economic and social influence on contemporary society [1](#jcmm13295-bib-0001){ref-type="ref"}. Consequently, there is a growing demand for effective therapies to cure or prevent OA, in particular with respect to the early onset of the so‐called PTOA, mostly affecting the middle‐aged population [2](#jcmm13295-bib-0002){ref-type="ref"}. Due to the complexity of its pathogenesis, the underlying molecular mechanisms are still incompletely understood and pharmacotherapeutic approaches are largely insufficient so far.

Research findings showed that blunt cartilage impact provokes loss of viable cells by acute necrosis and ongoing apoptosis [3](#jcmm13295-bib-0003){ref-type="ref"}, [4](#jcmm13295-bib-0004){ref-type="ref"}. Furthermore, surviving chondrocytes exhibit aberrant overexpression of catabolic collagenases and aggrecanases, such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), causing subsequent degradation of the extracellular matrix (ECM) [5](#jcmm13295-bib-0005){ref-type="ref"}, [6](#jcmm13295-bib-0006){ref-type="ref"}. Simultaneously, biosynthesis of the main ECM components type II collagen and aggrecan [6](#jcmm13295-bib-0006){ref-type="ref"} diminishes during OA progression, inter alia through chondrocyte desensitization towards insulin‐like growth factor 1 (IGF‐1) [7](#jcmm13295-bib-0007){ref-type="ref"}, [8](#jcmm13295-bib-0008){ref-type="ref"}. The pathologic changes in chondrocyte behaviour are largely triggered by the release of pro‐inflammatory cytokines as well as accumulation of reactive oxygen (ROS) and nitrogen (RNS) species [9](#jcmm13295-bib-0009){ref-type="ref"}, [10](#jcmm13295-bib-0010){ref-type="ref"}. Moreover, availability of bone morphogenetic protein 7 (BMP7), another chondroanabolic growth factor, shows a decline in elderly and arthritic cartilage [11](#jcmm13295-bib-0011){ref-type="ref"}, [12](#jcmm13295-bib-0012){ref-type="ref"}. In conjunction with the decrease in anabolic processes, the prevalent excess of matrix‐degrading proteases provokes a disastrous misbalance, ending up in progressive cartilage degeneration [13](#jcmm13295-bib-0013){ref-type="ref"}.

Previously, we implemented an antioxidative therapy approach based on NAC, which exhibits potent cell and chondroprotective features after *ex vivo* cartilage trauma [14](#jcmm13295-bib-0014){ref-type="ref"}, [15](#jcmm13295-bib-0015){ref-type="ref"}. The neutralization of harmful ROS/RNS by NAC protects chondrocytes from apoptosis and attenuates activation of redox‐sensitive signalling pathways, responsible for catabolic gene expression. Apart from this, NAC‐mediated suppression of COL2A1 gene expression indicated an adverse impact on cartilage anabolism [14](#jcmm13295-bib-0014){ref-type="ref"}. In the following study, we tried to countervail this potential drawback, by parallel stimulation with a pro‐anabolic growth factor. To sustain or restore the chondrogenic potential of the surviving chondrocytes, we compared three pro‐anabolic growth factors, commonly discussed as promising candidates for cartilage regeneration: IGF‐1 [7](#jcmm13295-bib-0007){ref-type="ref"}, [16](#jcmm13295-bib-0016){ref-type="ref"}, [17](#jcmm13295-bib-0017){ref-type="ref"}, BMP7 [18](#jcmm13295-bib-0018){ref-type="ref"}, [19](#jcmm13295-bib-0019){ref-type="ref"}, [20](#jcmm13295-bib-0020){ref-type="ref"} and fibroblast growth factor 18 (FGF18) [21](#jcmm13295-bib-0021){ref-type="ref"}, [22](#jcmm13295-bib-0022){ref-type="ref"}, [23](#jcmm13295-bib-0023){ref-type="ref"}. All approaches were evaluated by a variety of outcome parameters, referring to central pathogenetic aspects of PTOA: (*i*) cell viability, (*ii*) gene expression of ECM‐destructive enzymes as well as relevant ECM components, (*iii*) levels of anabolic and catabolic biomarkers, representing the matrix turnover [24](#jcmm13295-bib-0024){ref-type="ref"}, and (*iv*) histological tissue characteristics.

To our knowledge, this is not only the first comparative validation regarding the efficacy of the present growth factors in a human *ex vivo* cartilage trauma model, but also the first multidirectional approach in this context. Consequently, this study exhibits an informative overview of the respective advantages and disadvantages and takes first steps on a new path in preventing or delaying the onset of PTOA.

Materials and methods {#jcmm13295-sec-0002}
=====================

Specimen preparation and cultivation conditions {#jcmm13295-sec-0003}
-----------------------------------------------

Human cartilage was obtained from donors undergoing total knee joint replacement due to OA. Informed consent was obtained from all patients according to the terms of the Ethics Committee of the University of Ulm. Overall, macroscopically intact tissue samples (International Cartilage Repair Society score ≤1) [25](#jcmm13295-bib-0025){ref-type="ref"} from femoral condyles of 24 patients (mean age 70 years, ranging 50--82 years) were included in the study. Full‐thickness cartilage explants (Ø = 6 mm) were harvested, weighed and cultivated in serum‐containing medium for 24 hrs in an incubator (37°C, 5% CO~2~, 95% humidity). Afterwards, the explants were traumatized and cultivated up to 14 days in serum‐free medium (media composition: S1 in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}).

Ethics {#jcmm13295-sec-0004}
------

This study was performed in accordance with the Declaration of Helsinki and the guidelines of the Ethical Committee of the University of Ulm.

Impact loading and subsequent treatment {#jcmm13295-sec-0005}
---------------------------------------

Cartilage explants were subjected to a single impact load of 0.59 J (approximately 0.2 sec.) using a drop‐tower model as previously described [14](#jcmm13295-bib-0014){ref-type="ref"}, [26](#jcmm13295-bib-0026){ref-type="ref"}. Unloaded explants served as controls. Impacted/unimpacted cartilage explants were incubated w/and w/o therapeutic additives: a growth factor (100 ng/ml rhIGF‐1, 200 ng/ml rhFGF18 or 100 ng/ml rhBMP7; Peprotech, Hamburg, Germany) w/or w/o N‐acetyl‐L‐cysteine (2 mM or 3.5 mM NAC, Sigma‐Aldrich, Taufkirchen, Germany). Fresh additives were added concomitantly with medium change every 2--3 days.

mRNA isolation and cDNA synthesis {#jcmm13295-sec-0006}
---------------------------------

For total RNA isolation, cryopreserved cartilage explants were pulverized with a microdismembrator S (B. Braun Biotech, Melsungen, Germany). Subsequently, RNA was isolated using the Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). RNA was reverse transcribed with the Omniscript RT Kit (Qiagen) and used for quantitative real‐time PCR analysis (StepOnePlus™ Real‐Time PCR System, Applied Biosystems, Darmstadt, Germany).

Quantitative real‐time polymerase chain reaction (qRT‐PCR) {#jcmm13295-sec-0007}
----------------------------------------------------------

Determination of the relative expression levels was performed by means of qRT‐PCR analysis (2^−ΔΔCt^ method). To detect desired sequences, TaqMan^®^ Gene Expression Master Mix for TaqMan^®^ Gene Expression Assay (both Applied Biosystems) was used for following probes: Hs00153936_m1 (ACAN), Hs00192708_m1 (ADAMTS4), Hs00199841_m1 (ADAMTS5), Hs01034913_g1 (BMPR1A), Hs00176148_m1 (BMPR2), Hs00164004_m1 (COL1A1), Hs00264051_m1 (COL2A1), Hs00166657_m1 (COL10A1), Hs00179829_m1 (FGFR3), Hs02800695_m1 (HPRT1), Hs00609566_m1 (IGF1R), Hs00899658 (MMP‐1), Hs01548727_m1 (MMP‐2), Hs00968305_m1 (MMP‐3), Hs00233992_m1 (MMP‐13). Power SYBR^®^ Green PCR Master Mix (Applied Biosystems) was used for 18S rRNA, 5′‐CGCAGCTAGGAATAATGGAATAGG‐3′ (forward) and 5′‐CATGGCCTCAGTTCCGAAA‐3′ (reverse), and Platinum^®^ SYBR^®^ Green qPCR SuperMix‐UDG (Invitrogen, Darmstadt, Germany) for GAPDH, 5′‐TGGTATCGTGGAAGGACTCATG‐3′ (forward) and 5′‐TCTTCTGGGTGGCAGTGATG‐3′ (reverse). mRNA expression was determined by normalizing the expression levels separately to the endogenous controls (18S rRNA, GAPDH and HPRT1), and subsequently calculating the ratio mean values in relation to the gene expression level of the untreated, unimpacted control.

Live/dead cell cytotoxicity assay {#jcmm13295-sec-0008}
---------------------------------

To determine the percentage of viable cells, a Live/Dead^®^ Viability/Cytotoxicity Assay (Molecular Probes, Invitrogen) was performed. Unfixed tissue sections (0.5 mm thickness) were stained with 1 μM calcein AM and 2 μM ethidium homodimer‐1 for 30 min. After washing in PBS, they were microscopically analysed by means of a z‐stack module (software AxioVision, Carl Zeiss, Jena, Germany) (S2 in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}).

Analysis of culture media {#jcmm13295-sec-0009}
-------------------------

Quantity of biomarker release into culture media was evaluated by means of enzyme‐linked immunosorbent assays (ELISAs): secreted MMP‐13 was determined using the Human Quantikine ELISA kit (RayBiotech, Norcross, GA, USA). Evaluation of type II collagen synthesis was performed using a CPII ELISA (Ibex, Quebec, Canada). The assay quantifies type II collagen carboxy propeptide (CP II) cleaved from procollagen II after its release into the matrix and directly correlates with newly synthetized type II collagen. Degradation of type II collagen was measured using a C2C ELISA (Ibex), detecting a neoepitope generated during collagenase‐mediated breakdown of type II collagen. The total amount of MMP‐13, C2C and CP II, respectively, was relativized on the weight multiplied by cell viability of the corresponding cartilage explant [14](#jcmm13295-bib-0014){ref-type="ref"}.

Histological and immunohistochemical analysis {#jcmm13295-sec-0010}
---------------------------------------------

Staining methods are briefly described in the (S5 in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}).

Statistical analysis {#jcmm13295-sec-0011}
--------------------

Experiments were analysed using GraphPad Prism version 6.0 h (GraphPad Software). Data sets with *n* ≥ 5 were tested for outliers with the Grubbs outlier test. Outliers were not included in statistical analyses. For parametric data sets, a one‐way analysis of variance ([anova]{.smallcaps}) with Bonferroni post‐test was used. Nonparametric data sets were analysed by a Kruskal--Wallis test with Dunn′s post‐test. Significant level was set to α = 0.05. Values in diagrams are given as boxplots (median; whiskers: min to max).

Results {#jcmm13295-sec-0012}
=======

BMP7 and IGF‐1, but not FGF18, exhibit chondroanabolic qualities referring to anabolic gene expression {#jcmm13295-sec-0013}
------------------------------------------------------------------------------------------------------

To ensure the chondrocytes responsiveness to the applied growth factor concentrations, effects of IGF‐1, FGF18 or BMP7 on gene expression pattern of impacted and unimpacted cartilage explants, respectively, were evaluated first (Table [1](#jcmm13295-tbl-0001){ref-type="table-wrap"}).

###### 

Effects of growth factors on anabolic and catabolic gene expression pattern of human cartilage explants after 7 days

                IGF‐1 (*n* ≥ 8)                                        FGF18 (*n* ≥ 6)   BMP7 (*n* ≥ 8)                                                                                                           
  ------------- ------------------------------------------------------ ----------------- ---------------- ----------- ------------- ----------- ------------- ----------- ------------- ----------- ------------- -----------
  Target gene   Fold change[\*](#jcmm13295-note-0001){ref-type="fn"}   *P*‐value         Fold change      *P*‐value   Fold change   *P*‐value   Fold change   *P*‐value   Fold change   *P*‐value   Fold change   *P*‐value
  ADAMTS4       4.0                                                    0.5487            −1.7             \>0.9999    *16 .0*       \<0.0001    1.2           0.8642      1.7           \>0.9999    −1.9          \>0.9999
  ADAMTS5       1.8                                                    0.4953            −1.5             0.4488      *6.2*         \<0.0001    *1.9*         0.0073      *2.7*         0.0143      −1.1          \>0.9999
  MMP‐1         *2.3*                                                  0.0067            1.1              \>0.9999    *3.7*         \<0.0001    −1.3          \>0.9999    1.6           0.4991      1.2           0.9935
  MMP‐2         3.8                                                    0.0741            −1.7             0.1771      *8.0*         \<0.0001    −*4.3*        0.0125      1.9           \>0.9999    −1.6          0.2522
  MMP‐3         1.2                                                    \>0.9999          1.0              \>0.9999    *3.4*         \<0.0001    1.3           0.5551      1.2           \>0.9999    1.1           \>0.9999
  MMP‐13        2.6                                                    0.0526            1.2              0.4446      *18.5*        0.0007      1.8           0.1002      2.3           \>0.9999    *−*1.6        0.3856
  COL1A1        8.0                                                    0.1302            *−5.5*           0.0247      *16.7*        0.0008      −*18.1*       0.0247      5.9           0.14        *−8.6*        0.0218
  COL2A1        *2.6*                                                  \<0.0001          *1.5*            0.0069      *−2.8*        0.0308      *−3.9*        0.0003      *1.5*         0.0283      *2.1*         \<0.0001
  COL10A1       *3.9*                                                  0.0489            *−*1.8           0.6805      1.9           \>0.9999    *−*1.3        \>0.9999    1.2           \>0.9999    1.2           \>0.9999
  ACAN          1.2                                                    0.2004            *−*1.1           \>0.9999    *−2.9*        \<0.0001    *−2.9*        \<0.0001    *1.3*         0.0375      *1.4*         0.0017

C= untreated, unimpacted control, GF= growth factor, T= traumatized, T+GF= traumatized and stimulated with growth factor. **\***Significant differences between groups (fold change) were italicized.

John Wiley & Sons, Ltd

After stimulation with IGF‐1, unimpacted cartilage explants showed enhanced gene expression levels of catabolic enzymes ADAMTS‐4 (*P* = 0.5487), MMP‐1 (*P* = 0.0067), MMP‐2 (*P* = 0.0741) and MMP‐13 (*P* = 0.0526). Likewise, IGF‐1 stimulation significantly enhanced the gene expression of COL2A1 and COL10A1 (*P* \< 0.0001 and *P* = 0.0489, respectively) as well as COL1A1 by trend. In impacted cartilage explants, gene expression of COL2A1 (*P* = 0.0069) was significantly increased after IGF‐1 stimulation, while that of COL1A1 (*P* = 0.0247) was suppressed.

Stimulation of unimpacted cartilage explants with FGF18 showed significant induction of catabolic gene expression in case of ADAMTS‐4 (*P* \< 0.0001), ADAMTS‐5 (*P* \< 0.0001), MMP‐1 (*P* \< 0.0001), MMP‐2 (*P* \< 0.0001), MMP‐3 (*P* \< 0.0001) and MMP‐13 (*P* = 0.0007), as well as COL1A1 (*P* = 0.0008). Simultaneously, FGF18 stimulation significantly suppressed the expression of ACAN (*P* \< 0.0001) and COL2A1 (*P* = 0.0308). In impacted cartilage explants, FGF18 stimulation significantly suppressed trauma‐induced expression of MMP2 (*P* = 0.0125) and COL1A1 (*P* = 0.0247) but also ACAN (*P* \< 0.0001) and COL2A1 (*P* = 0.0003).

In unimpacted cartilage explants, BMP7 stimulation significantly increased the expression of COL2A1 (*P* = 0.0283) and ACAN (*P* = 0.0375) but also ADAMTS5 (*P* = 0.0143) as well as COL1A1 by trend. As compared to non‐stimulated impacted cartilage explants, BMP7 treatment significantly enhanced levels of COL2A1 (*P* \< 0.0001) and ACAN (*P* = 0.0017). As stimulation with growth factors revealed largely significant influence on the expression of the tested target genes, some efficacy has been considered.

Multidirectional antioxidative and chondroanabolic therapy of impacted cartilage tissue shows no additional benefit as compared to the mono‐therapeutic approaches {#jcmm13295-sec-0014}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Seven days after trauma (T), gene expression of all tested ECM‐destructive proteases was significantly elevated as compared to control level (C): ADAMTS‐4 (9.2‐fold, *P* \< 0.0001), ADAMTS‐5 (threefold, *P* = 0.0032), MMP‐1 (11.5‐fold, *P* \< 0.0001), MMP‐2 (fourfold, *P* \< 0.0001), MMP‐3 (2.3‐fold, *P* \< 0.0001) and MMP‐13 (10.5‐fold *P* \< 0.0001). While the expression of COL2A1 and ACAN was rather down‐regulated, that of COL1A1 was significantly enhanced after trauma (25.7‐fold, *P* = 0.0005). Moreover, trauma induced the gene expression of COL10A1 by trend (2.9‐fold).

Additional IGF‐1 stimulation largely reversed favourable effects of NAC treatment on expression of ACAN (Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}D), ADAMTS‐4, MMP‐2 and MMP‐13 (Fig. [1](#jcmm13295-fig-0001){ref-type="fig"}A, D and F); however, MMP‐2 gene expression was significantly suppressed using a higher NAC concentration (−5.7‐fold, *P* = 0.0047). NAC‐induced gene expression of COL10A1 was likewise reversed by IGF‐1 (Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}C). Although 2 mM NAC treatment usually caused significant suppression of COL2A1 (Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}B), it was significantly enhanced in combination with IGF‐1 (twofold, *P* \< 0.0001). This effect was eliminated by the use of the higher NAC concentration.

![Effects of growth factors with NAC on trauma‐induced gene expression of ECM‐destructive enzymes. Impacted human cartilage explants were continuously treated by growth factors and NAC (2 mM or 3.5 mM). 7 days post‐trauma, gene expression levels of ECM‐destructive enzymes (**A**) ADAMTS‐4, (**B**) ADAMTS‐5, (**C**) MMP‐1, (**D**) MMP‐2, (**E**) MMP‐3 and (**F**) MMP‐13 were analysed by qRT‐PCR. T= traumatized, +I/B/F= stimulated by IGF‐1 (purple)/FGF18 (red)/BMP7 (green). Significant differences between groups were depicted as: \[*versus* T\] \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001; \[*versus* C\] c= *P* \< 0.01; \[GF versus GF\] ^\$^ *P* \< 0.05, ^\$\$\$^ *P* \< 0.001, ^\$\$\$\$^ *P* \< 0.0001. T: *n* ≥ 20; T+N: *n* ≥ 13 (2 mM), *n* ≥ 9 (3.5); T+N+I: *n* ≥ 8 (2 mM), *n* = 4 (3.5 mM); T+N+F: *n* ≥ 5 (2 mM), *n* = 5 (3.5 mM); T+N+B: *n* ≥ 8 (2 mM), *n* = 5 (3.5 mM).](JCMM-22-77-g001){#jcmm13295-fig-0001}

![Effects of growth factors with NAC on trauma‐related alterations in gene expression of ECM components. Impacted human cartilage explants were continuously treated by growth factors and NAC (2 mM or 3.5 mM). 7 days post‐trauma, gene expression levels of ECM components (**A**) type I collagen (COL1A1), (**B**) type II collagen (COL2A1), (**C**) type X collagen (COL10A1) and (**D**) aggrecan (ACAN) were analysed by qRT‐PCR. T= traumatized, +I/B/F= stimulated by IGF‐1 (purple)/FGF18 (red)/BMP7 (green). Significant differences between groups were depicted as: \[*versus* T\] \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001; \[*versus* C\] c= *P* \< 0.05; \[GF *versus* GF\] ^\$^ *P* \< 0.05, ^\$\$^P \< 0.01, ^\$\$\$\$^ *P* \< 0.0001. T: *n* ≥ 20; T+N: *n* ≥ 13 (2 mM), *n* ≥ 9 (3.5); T+N+I: *n* ≥ 13 (2 mM), *n* = 4 (3.5 mM); T+N+F: *n* ≥ 6 (2 mM), *n* = 5 (3.5 mM); T+N+B: *n* ≥ 8 (2 mM), *n* = 5 (3.5 mM).](JCMM-22-77-g002){#jcmm13295-fig-0002}

Combined treatment with FGF18 and NAC significantly suppressed the trauma‐induced expression of MMP‐2 (\[2 mM\] −8.2‐fold, *P* = 0.0006; \[3.5 mM\] −10.4‐fold, *P* = 0.0004; Fig. [1](#jcmm13295-fig-0001){ref-type="fig"}D) and MMP‐13 (\[3.5 mM\] −14.8‐fold, *P* = 0.0045; Fig. [1](#jcmm13295-fig-0001){ref-type="fig"}F), but also ACAN (\[2 mM\] *P* = 0.05, relative to C; Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}D) and COL2A1 (\[2 mM\] and \[3.5 mM\] *versus* C and T: *P* \< 0.0001; Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}B). Addition of NAC, completely abolished the inducing effect of BMP7 on COL2A1 (\[2 mM\] *versus* C and T: *P* \< 0.0001, \[3.5 mM\] *versus* T: *P* = 0.0188; *versus* C: *P* \< 0.0001, Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}B), whereas ACAN (Fig. [2](#jcmm13295-fig-0002){ref-type="fig"}D) was further enhanced, indicating an additive effect of the two therapeutics (\[2 mM\] 1.5‐fold, *P* = 0.0206; \[3.5 mM\] 2.1‐fold, *P* = 0.007). Except for ADAMTS‐5 and MMP‐3 (Fig. [1](#jcmm13295-fig-0001){ref-type="fig"}B and E), NAC‐mediated suppression of trauma‐induced catabolic gene expression was broadly maintained, but not significantly enhanced in combination with BMP7: \[2 mM\] ADAMTS‐4: −3.5‐fold, *P* = 0.0137; MMP‐2: −3.8‐fold, *P* = 0.0004; MMP‐13: −11.9‐fold, *P* \< 0.0001; \[3.5 mM\] ADAMTS‐4: −7.3‐fold, *P* = 0.0134; MMP‐1: −14.7‐fold, *P* = 0.0017; MMP‐2: −7‐fold, *P* = 0.0001; MMP‐13: −21.9‐fold, *P* \< 0.0001.

Elevated COL10A1 gene expression after NAC treatment tended to be lowered in combination with growth factor stimulation, but was still significantly increased with FGF18 (*versus* C: \[2 mM\] *P* = 0.0096, \[3.5 mM\]: *P* = 0.0185) or BMP7 (*versus* C: \[2 mM\] *P* = 0.0004, \[3.5 mM\]: *P* = 0.0016). Moreover, trauma‐induced gene expression of ADAMTS‐5 (Fig. [1](#jcmm13295-fig-0001){ref-type="fig"}B) was significantly enhanced by the combined treatment using NAC and FGF18 (\[3.5 mM\] *P* = 0.05) or BMP7 (\[2 mM\] *P* \< 0.0001, \[3.5 mM\]: *P* = 0.0135).

After all, NAC‐mediated induction of COL10A1 and suppression of COL2A1 gene expression, respectively, were completely eliminated 7 days after deprivation of NAC application (Fig. S3A and C in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}).

Additionally, gene expression levels of corresponding growth factor receptors BMP receptor 1A (BMPR1A, Fig. S4A in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}) and 2 (BMPR2, Fig. S4B in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}), IGF‐1 receptor (IGF1R, Fig. S4C in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}) and FGF receptor 3 (FGFR3, Fig. S4D in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}) were exemplarily evaluated. After trauma, gene expression levels of IGF1R and FGFR3 were enhanced by trend. mRNA levels of IGFR1 were significantly induced by BMP7 stimulation (*versus* C \[C+B\] *P* = 0.0167). While both BMPR1A and BMPR2 were significantly enhanced by combined treatment with BMP7 and NAC (*versus* C: *P* = 0.0263 and *P* \< 0.0001, respectively), FGFR3 was significantly attenuated after FGF18 stimulation in all tested approaches (*versus* C: \[C+F\] *P* = 0.0018; \[T+F\] *P* = 0.0463; \[T+F+N\] *P* = 0.0364).

FGF18 and BMP7 exhibit cell protective qualities after cartilage trauma, whereas IGF‐1 only shows low efficiency {#jcmm13295-sec-0015}
----------------------------------------------------------------------------------------------------------------

Cell viability of the cartilage explants was evaluated 7 days post‐trauma (Fig. [3](#jcmm13295-fig-0003){ref-type="fig"}). Traumatization of cartilage explants caused significant decrease in cell viability (−28.6%, *P* \< 0.0001). Although stimulation with growth factors significantly increased cell viability of impacted cartilage explants (T+IGF: +5.9%, *P* = 0.007; T+FGF: +12.8%, *P* \< 0.0001; T+BMP: +14.4%, *P* \< 0.0001), it was still significantly lower than C. IGF‐1 had an inferior efficacy as compared to FGF18 (−5.7%, *P* = 0.3078) and BMP7 (−8%, *P* = 0.0098). The same could be observed in the combined approach with 2 mM NAC: cell viability of T+N+IGF was still significantly lower as C (−11%, *P* = 0.0013), T+N+FGF (−10.5%, *P* = 0.0463) and T+N+BMP (−10%, *P* = 0.0411). Nevertheless, cell viability of impacted cartilage explants simultaneously treated with 2 mM NAC and FGF18 or BMP7, respectively, was equal to that of C or T+N (mean difference to C ranging 0.7127--1.373). Even in combination with 3.5 mM NAC (exemplarily tested), IGF‐1 stimulation could not achieve full recovery of the cell viability (−6.76%). Moreover, the higher NAC concentration was rather disadvantageous in combination with FGF18 and BMP7.

![Effects of growth factors w/and w/o NAC on cell viability after cartilage trauma. Impacted human cartilage explants were continuously treated by GF w/and w/o NAC (\[2 mM\]: *n* ≥ 7; \[3.5 mM\]: *n* ≥ 4) for 7 days and subsequently analysed by Live/Dead^®^ Viability/Cytotoxicity Assay. C= control, T= traumatized, +I/B/F= stimulated by IGF‐1 (purple)/FGF18 (red)/BMP7 (green). Significant differences between groups were depicted as: \[*versus* T\] \*\**P* \< 0.01, \*\*\*\**P* \< 0.0001; \[*versus* C\] c= *P* \< 0.001; \[*versus* T+N\] TN= *P* \< 0.05; \[GF *versus* GF\] ^\$^ *P* \< 0.05, ^\$\$^ *P* \< 0.01.](JCMM-22-77-g003){#jcmm13295-fig-0003}

FGF18 and BMP7 show significant chondroprotective qualities w/and w/o NAC {#jcmm13295-sec-0016}
-------------------------------------------------------------------------

The amount of MMP‐13 and the cleavage‐specific neoepitope C2C, generated by collagenases MMP‐1, MMP‐8 and MMP‐13 during breakdown of type II collagen, were used as representative biomarkers of the catabolism. Quantification of secreted MMP‐13 (Fig. [4](#jcmm13295-fig-0004){ref-type="fig"}A and B) widely confirmed the findings of gene expression analysis: MMP‐13 release was significantly increased after FGF18 stimulation of unimpacted cartilage explants (3.7‐fold, *P* = 0.0111). While the trauma‐induced release of MMP‐13 (Fig. [4](#jcmm13295-fig-0004){ref-type="fig"}B) was still significantly enhanced after treatment with either FGF18 (4.7‐fold, *P* = 0.036) or IGF‐1 (4.7‐fold, *P* = 0.014), it was lowered in trend by BMP7 (−2‐fold, *P* = 0.138). Combined treatment of impacted cartilage explants significantly decreased the amount of secreted MMP‐13: T+N+I (\[3.5 mM\] −4.2‐fold, *P* = 0.0816), T+N+F (\[2 mM\] −4.8‐fold, *P* = 0.022; \[3.5 mM\] −10.4‐fold, *P* = 0.0104), T+N+B (\[2 mM\] −15.4‐fold, *P* = 0.0039; \[3.5 mM\] −7.2‐fold, *P* = 0.0169). MMP‐13 concentrations were still significantly higher after combined treatment using IGF‐1 and 2 mM NAC as compared to the corresponding treatments using FGF18 (4.9‐fold, *P* = 0.0342) or BMP7 (15.6‐fold, *P* = 0.0072).

![Effects of growth factors w/or w/o NAC on OA‐associated catabolic biomarkers. (**B, D**) Impacted human cartilage explants were continuously treated by GF w/and w/o NAC (2 mM, *n* ≥ 5; or 3.5 mM, *n* ≥ 4). (**A, C**) Corresponding unimpacted controls were stimulated by GF;*n* ≥ 5 each. Amount of (**A, B**) secreted MMP‐13 and (**C, D**) generated type II collagen cleavage product C2C in the culture media was analysed 7 days post‐trauma by means of corresponding ELISAs. C= unimpacted control, T= traumatized, GF= growth factor, +I/B/F= stimulated by IGF‐1 (purple)/FGF18 (red)/BMP7 (green). Significant differences between groups were depicted as: \[*versus* T\] \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001; \[*versus* C\] c= *P* \< 0.05; \[GF *versus* GF\] ^\$^ *P* \< 0.05, ^\$\$^ *P* \< 0.01, ^\$\$\$^ *P* \< 0.001.](JCMM-22-77-g004){#jcmm13295-fig-0004}

Except for C+FGF18, the amount of C2C (Fig. [4](#jcmm13295-fig-0004){ref-type="fig"}C and D) largely correlated with the findings of the secretion of MMP‐13: Trauma‐induced increase of C2C (1.7‐fold, *P* \< 0.0001, Fig. [4](#jcmm13295-fig-0004){ref-type="fig"}D) was significantly lowered by FGF18 (−1.6‐fold, *P* \< 0.0001) and BMP7 (−1.4‐fold, *P* = 0.0132). In combination with NAC, trauma‐induced breakdown of type II collagen was additionally reduced: T+N+I (\[2 mM\] −1.3‐fold, *P* = 0.0157; \[3.5 mM\] −1.9‐fold, *P* \< 0.0001), T+N+F (\[2 mM\] −2.3‐fold; \[3.5 mM\] −2.5‐fold, both *P* \< 0.0001) and T+N+B (\[2 mM\] −1.6‐fold, *P* = 0.001; \[3.5 mM\] −2‐fold, *P* \< 0.0001). Moreover, FGF18 (w/or w/o 2 mM NAC) had a significant higher effect on prevention of C2C‐release after trauma as compared to corresponding treatments using IGF‐1 (\[w/o NAC\] *P* = 0.0005; \[2 mM\] *P* = 0.0018) and even lowered the amount of C2C in the media of unimpacted explants as compared to IGF‐1 (*P* = 0.0126) and BMP7 (*P* = 0.0045).

IGF‐1 and BMP7 significantly promote type II collagen biosynthesis, whereas their combination with NAC abolishes this effect {#jcmm13295-sec-0017}
----------------------------------------------------------------------------------------------------------------------------

Content of CP II in culture media was considered as an anabolic biomarker and confirmed the findings of gene expression analysis to a great extent: IGF‐1 and BMP7 stimulation significantly supported type II collagen biosynthesis of unimpacted (C+I: 1.38‐fold, *P* = 0.0251; C+B: 1.4‐fold, *P* = 0.0134, Fig. [5](#jcmm13295-fig-0005){ref-type="fig"}A) as well as impacted cartilage explants (T+I: 1.48‐fold, *P* \< 0.0001; T+B: 1.33‐fold, *P* = 0.0131, (Fig. [5](#jcmm13295-fig-0005){ref-type="fig"}B). FGF18 showed no inductive but rather suppressive effect on type II collagen biosynthesis, which was significant as compared to IGF‐1 (C+F: −1.6‐fold, *P* = 0.0034; T+F: −1.7‐fold, *P* \< 0.0001) or BMP7 (C+F: −1.7‐fold, *P* = 0.002; T+F: −1.6‐fold, *P* = 0.0001). Addition of NAC to any growth factor (Fig. [5](#jcmm13295-fig-0005){ref-type="fig"}B) significantly reduced the amount of CP II in culture media of impacted cartilage explants compared to both T and C (*P* \< 0.0001, each).

![Effects of growth factors w/or w/o NAC on type II collagen synthesis as anabolic biomarker. (**B**) Impacted human cartilage explants were continuously treated by GF w/and w/o NAC (2 mM, *n* ≥ 5; or 3.5 mM, *n* ≥ 4). (**A**) Corresponding unimpacted controls were stimulated by GF;*n* ≥ 5 each. Amount of CPII in the culture media was analysed 7 days post‐trauma by means of ELISA. C= unimpacted control, T= traumatized, GF= growth factor, +I/B/F= stimulated by IGF‐1 (purple)/FGF18 (red)/BMP7 (green). Significant differences between groups were depicted as: \[*versus* T\] \**P* \< 0.05, \*\*\*\**P* \< 0.0001; \[*versus* C\] c= *P* \< 0.05; \[GF *versus* GF\] ^\$\$^ *P* \< 0.01, ^\$\$\$^ *P* \< 0.001, ^\$\$\$\$^ *P* \< 0.0001.](JCMM-22-77-g005){#jcmm13295-fig-0005}

To test reversibility of type II collagen biosynthesis suppression by NAC, antioxidative therapy was exemplarily deprived after 7 days. Quantification of CP II revealed significant recovery of type II collagen synthesis (*P* = 0.0133) 7 days after deprivation of NAC (14 days post‐trauma), compared to continuously treated impacted cartilage explants (Fig. S3B in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}).

Evaluation of the histomorphologic cartilage quality largely confirmed the previous findings {#jcmm13295-sec-0018}
--------------------------------------------------------------------------------------------

Histomorphologic cartilage tissue characteristics were evaluated exemplarily in terms of type II collagen and glycosaminoglycan (GAG) content, as well as cell density and distribution. 14 days after trauma, increased numbers of cell clones or clusters as well as column‐like stacking of the cells could be observed with and without growth factor stimulation (Fig. S5A in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}). Additional analysis of the cell distribution at an earlier time‐point (7 days post‐trauma) revealed less cell clusters and rather hypocellularity. NAC treatment appeared to lower the trauma‐induced cluster formation after 14 days. Moreover, type II collagen (Fig. S5B in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}) and GAG (Fig. S5C in Data [S1](#jcmm13295-sup-0001){ref-type="supplementary-material"}) staining were less intensive after traumatization as compared to C.

IGF‐1 stimulation of impacted cartilage explants resulted in higher GAG and type II collagen staining intensities. This effect was clearly inhibited in combination with NAC as described before. Surprisingly, NAC did not interfere with chondroanabolic influence of BMP7 and, furthermore, did not attenuate type II collagen staining intensities after mono‐therapeutic application. Once again, no pro‐anabolic influence was found after FGF18 stimulation.

Discussion {#jcmm13295-sec-0019}
==========

Overall, trauma‐induced pathomechanisms initiate several cellular knock‐on effects, as apoptosis, excessive expression of ECM‐destructive proteases and simultaneous decline of ECM‐synthesis. Additional release of pro‐inflammatory cytokines and accumulation of ROS/RNS, which are crucial key mediators, promote the onset and progression of PTOA [27](#jcmm13295-bib-0027){ref-type="ref"}. Regarding the complexity of PTOA pathogenesis, it would be utopian to search for a single panacea. As recently suggested by Chubinskaya and Wimmer, the ideal therapy should include pro‐anabolic as well as anti‐catabolic features and further support intrinsic regeneration [28](#jcmm13295-bib-0028){ref-type="ref"}. Based on the encouraging results of our recent study [14](#jcmm13295-bib-0014){ref-type="ref"}, a multidirectional therapy, combining the antioxidant NAC and additional chondroanabolic stimulation, seemed to be a promising strategy for approaching the challenging therapeutic requirements to prevent or ameliorate PTOA. Antioxidative treatment by NAC (2 mM or 3.5 mM) has been found to possess significant cell and chondroprotective features after *ex vivo* traumatization of human cartilage [14](#jcmm13295-bib-0014){ref-type="ref"}. NAC not only attenuated trauma‐induced gene expression of the ECM‐destructive enzymes ADAMTS‐4, MMP‐1, MMP‐2, MMP‐3 and MMP‐13, but also the secreted amount and proteolytic activity of MMPs, as shown for MMP‐2 and MMP‐13, respectively. Moreover, NAC administration abolished apoptotic cell death, guaranteeing a significant protection of chondrocyte viability after cartilage injury. Although NAC was found to enhance the gene expression of ACAN, it significantly suppressed that of COL2A1 [14](#jcmm13295-bib-0014){ref-type="ref"}. Therefore, the question of possible adverse reaction of NAC treatment concerning the ECM anabolism and maintenance of the chondrogenic phenotype of the surviving cells arouse. With respect to these achievements but also concerns, we assumed that the pro‐anabolic growth factors might complement the 'deficiencies' of NAC and suggested a mutual supportiveness between the two therapeutics.

The growth factor concentrations used throughout this study were determined by reliable bibliographic references [18](#jcmm13295-bib-0018){ref-type="ref"}, [21](#jcmm13295-bib-0021){ref-type="ref"}, [29](#jcmm13295-bib-0029){ref-type="ref"} and in‐house preliminary testing work, including gene expression analysis and chemotaxis assay, respectively (data not shown). Moreover, our current findings exhibited significant influences on mRNA and protein level after growth factor stimulation, which endorsed the efficacy of the applied concentrations. Although there are various studies dealing with these growth factors, most knowledge about their qualities was gained in cell culture [8](#jcmm13295-bib-0008){ref-type="ref"}, [17](#jcmm13295-bib-0017){ref-type="ref"}, [30](#jcmm13295-bib-0030){ref-type="ref"}, cytokine‐induced OA [7](#jcmm13295-bib-0007){ref-type="ref"}, [16](#jcmm13295-bib-0016){ref-type="ref"} as well as animal *in vitro* [21](#jcmm13295-bib-0021){ref-type="ref"} and *in vivo* [19](#jcmm13295-bib-0019){ref-type="ref"}, [22](#jcmm13295-bib-0022){ref-type="ref"} models, respectively. Therefore, our model might add valuable information about the therapeutic potential of growth factors relevance after blunt cartilage trauma (0.59 J) based on a human tissue culture model.

Fourteen days after trauma, increased incidence of cell clusters as well as column‐like cell distribution near the surface and within close proximity to the impact site were observed. Cell columns can usually be found in the deeper zones but are rather uncommon for the upper regions of healthy cartilage [31](#jcmm13295-bib-0031){ref-type="ref"}. Trauma‐induced cell proliferation and subsequent cluster formation may represent an initial attempt of intrinsic regeneration after cartilage injury and has been described as a hallmark of OA cartilage [31](#jcmm13295-bib-0031){ref-type="ref"}. Nevertheless, at the earlier time‐point (7 days), the tissue was rather hypocellular and the cell viability was significantly impaired due to necrotic and apoptotic events [3](#jcmm13295-bib-0003){ref-type="ref"}, [4](#jcmm13295-bib-0004){ref-type="ref"}, [14](#jcmm13295-bib-0014){ref-type="ref"}. Single therapy with IGF‐1, FGF18 or BMP7 for 7 days showed significant but only moderate recovery, amongst which BMP7 exhibited the best results. While proliferative and anti‐apoptotic characteristics have been previously described for IGF‐1 [32](#jcmm13295-bib-0032){ref-type="ref"}, [33](#jcmm13295-bib-0033){ref-type="ref"} and FGF18 [21](#jcmm13295-bib-0021){ref-type="ref"}, BMP‐7 is only known for its anti‐apoptotic quality so far [18](#jcmm13295-bib-0018){ref-type="ref"}, [20](#jcmm13295-bib-0020){ref-type="ref"}. Moreover, growth factor stimulation had divergent influence on the gene expression of anabolic and catabolic markers depending on whether the explants were previously impacted. Although IGF‐1, FGF18 and BMP7 tended to induce the gene expression of catabolic enzymes as well as type I collagen in unimpacted control tissue, the induction was attenuated and even mostly reversed in impacted cartilage explants.

In short, FGF18 was the strongest inducer of catabolic gene expression in unimpacted control tissue, whereas BMP7 and IGF‐1 had moderate adverse effects. While BMP7 tended to attenuate both trauma‐induced MMP‐13 secretion and breakdown of type II collagen, IGF‐1 reduced neither of them. Although FGF18 had no attenuating effect on secretion of MMP‐13, significant alleviation of type II collagen cleavage by FGF18 might indicate chondroprotective qualities of the growth factor. Similar prevention of type II collagen breakdown following single impact load was previously observed in a trauma‐model using horse cartilage explants [21](#jcmm13295-bib-0021){ref-type="ref"}. That FGF18 significantly ameliorated collagenase‐mediated cleavage of type II collagen despite enhanced MMP‐13 amounts might correlate with its suppressing effect on MMP‐2 gene expression. Activation of freshly secreted pro‐MMP‐13 is based on a proteolytic cascade, comprising the membrane‐associated MT1‐MMP (MMP‐14) and MMP‐2. Although MMP‐13 can also be directly activated by MT1‐MMP, the reaction is potentiated in the presence of MMP‐2. Further, MMP‐2, which itself is activated by MT1‐MMP, is a much faster activator of MMP‐13 than MT1‐MMP [34](#jcmm13295-bib-0034){ref-type="ref"}.

Unlike IGF‐1 and BMP7, FGF18 had detrimental impact on the expression of ACAN and COL2A1 in both unimpacted and traumatized cartilage explants, which was confirmed on protein level by quantifying the content of CP II in culture media. Although suppression of type II collagen has already been reported in some instances [21](#jcmm13295-bib-0021){ref-type="ref"}, [35](#jcmm13295-bib-0035){ref-type="ref"}, other *in vivo* studies demonstrated promising pro‐anabolic potential of FGF18 [22](#jcmm13295-bib-0022){ref-type="ref"}, [23](#jcmm13295-bib-0023){ref-type="ref"}. As currently described, FGF18 significantly down‐regulated type II collagen expression as well as hypertrophy markers and promoted osteogenesis during chondrogenic differentiation of isolated mesenchymal stem cells [36](#jcmm13295-bib-0036){ref-type="ref"}. Further, FGF18 was found to be expressed by hypertrophic chondrocytes adjacent to the tidemark, stimulating terminal differentiation in the osteochondral tissue at the growth plate. It can be assumed that FGF18 is essential for both chondrogenesis and osteogenesis during skeletal development. However, it appears that FGF18 affects chondrogenesis in a negative way, while having a positive impact on osteogenesis [37](#jcmm13295-bib-0037){ref-type="ref"}. Another critical aspect was revealed by gene expression analysis of FGFR3, which was significantly down‐regulated after FGF18 stimulation. While FGF2 is thought to induce catabolic processes by signalling *via* FGFR1, FGF18 exhibits highest receptor specificity to 'anabolic' FGFR3 [38](#jcmm13295-bib-0038){ref-type="ref"}, [39](#jcmm13295-bib-0039){ref-type="ref"}. According to previous studies, negative regulation of FGFR3 can result from FGF2‐mediated FGFR1‐signalling, whereas no negative feedback of FGF18 on its receptor has been described so far. As it has been shown that the expression ratio of FGFR1 to FGFR3 is highly overbalanced in OA cartilage and FGFR1 expression can be additionally up‐regulated by FGF18, it could be possible that effects of endogenous FGF2 might be potentiated by FGF18 stimulation [39](#jcmm13295-bib-0039){ref-type="ref"}. As we found significant effects of FGF18 despite reduced FGFR3 gene expression, desensitization is rather improbable but might occur in the long run.

Summarizing our results of the chondroanabolic approach, we found that IGF‐1 and BMP7, but not FGF18, possess promising pro‐anabolic qualities after blunt cartilage injury as shown for ACAN and COL2A1 expression as well as type II collagen biosynthesis. Consequently, we identified IGF‐1 and BMP7 as potential candidates to promote the chondroanabolic behaviour in chondrocytes after cartilage trauma. Although FGF18 seemed to be unsuitable to promote anabolic processes, it still exhibited considerable cell‐ and chondroprotective qualities in the context of our human *ex vivo* trauma‐model. This way, it might indeed contribute to the ECM‐integrity by preventing excessive matrix depletion after cartilage trauma.

As NAC treatment already resulted in complete recovery of the cell viability after cartilage trauma, no additive effects were found regarding the combined approach. On the contrary, IGF‐1 largely impaired the NAC‐mediated cell and chondroprotection after trauma, as demonstrated by comparatively low cell viability, enhanced gene expression of ADAMTS‐4, MMP‐1, MMP‐3 and MMP‐13, as well as MMP‐13 secretion and cleavage of type II collagen. That IGF‐1 might lose its pro‐survival and anti‐catabolic attributes in adult human cartilage has already been reported [7](#jcmm13295-bib-0007){ref-type="ref"}. While it is assumed that chondrocyte desensitization towards IGF‐1 increases in correlation to accumulation of IGF‐1 binding proteins as well as ROS and NO, as occurring in elderly or osteoarthritic cartilage tissue [7](#jcmm13295-bib-0007){ref-type="ref"}, [40](#jcmm13295-bib-0040){ref-type="ref"}, efficacy of BMP7 was described as being unaffected by age or OA [18](#jcmm13295-bib-0018){ref-type="ref"}. Nevertheless, single IGF‐1 stimulation was capable to induce type II collagen expression, which indicates that the chondrocytes within the cartilage explants were still susceptible for the pro‐anabolic signalling promoted by IGF‐1 to a certain extent. However, it cannot be completely excluded that the osteoarthritic environment of tissue sampling or the age of the patients might have impaired the pro‐anabolic qualities of IGF‐1 in the context of our study. As NAC is known as an efficient scavenger of harmful ROS/RNS [41](#jcmm13295-bib-0041){ref-type="ref"}, it was expected that the effectiveness of IGF‐1 could be increased in presence of the antioxidant. In fact, a possibly synergistic interaction of IGF‐1 and NAC (2 mM) was initially found regarding COL2A1 expression after trauma, although subsequent analysis of the culture media could not confirm actual enhancement of type II collagen on protein level.

Although the anti‐catabolic qualities of BMP7 [18](#jcmm13295-bib-0018){ref-type="ref"}, [19](#jcmm13295-bib-0019){ref-type="ref"}, [20](#jcmm13295-bib-0020){ref-type="ref"} actually appeared to collaborate with NAC‐mediated suppression of catabolic gene expressions, the combination seemed to induce transcription of ADAMTS‐5. Comparable trends were found for FGF18. Unlike most of the other investigated collagenases and aggrecanases, ADAMTS‐5 is not induced by redox‐sensitive pathways but might be triggered by mechanical stress and subsequent activation of the runt‐related transcription factor (RUNX)‐2 [42](#jcmm13295-bib-0042){ref-type="ref"}, [43](#jcmm13295-bib-0043){ref-type="ref"}. Therefore, it remains unclear how NAC or the growth factors might have contributed to the enhanced gene expression of ADAMTS‐5. Along with MMP‐13, ADAMTS‐5 is dealt as one of the most crucial ECM‐degrading enzyme associated with OA pathogenesis [5](#jcmm13295-bib-0005){ref-type="ref"}. As it is suggested that NAC might act as a direct inhibitor of released MMP‐3 in a post‐translational manner, the presence of NAC might prevent ADAMTS‐5 activation by MMP‐3 [14](#jcmm13295-bib-0014){ref-type="ref"}, [44](#jcmm13295-bib-0044){ref-type="ref"}.

Regarding NAC‐induced gene expression of type X collagen after trauma, the underlying mechanisms remain largely unclear. Although type X collagen and MMP‐13 are both common biomarkers of hypertrophic chondrocytes, their expression is modulated by various transcriptional regulators and might occur uncoupled [45](#jcmm13295-bib-0045){ref-type="ref"}. This could explain why NAC exhibited divergent influence on the expression of the corresponding genes. Moreover, previous findings indicated that type X collagen is mainly associated with the early stages of OA and was hardly present in later stages while MMP‐13 remained elevated [46](#jcmm13295-bib-0046){ref-type="ref"}. Brew *et al. suggested* that COL10A1‐expressing chondrocytes undergo apoptosis, which might have been prevented by the anti‐apoptotic effects of BMP7, FGF18 and NAC in our study. Another interesting interaction of NAC and BMP7 was shown for the gene expression levels of BMPR1A and 2, which were both enhanced in a synergistic manner, after combined application. Whether and to what degree this might contribute to increased mRNA levels of ADAMTS‐5, COL10A1 or ACAN and other additive effects observed throughout this study should be addressed in future studies.

Although exemplary immunohistochemical staining did not reveal detrimental effects of NAC‐mediated suppression of type II collagen expression on the cartilage characteristics, neither alone nor in combination with BMP7, we are cautiously optimistic as the validity might be limited by the low number of donors. As a consequence of the results we found for the parallel multidirectional approach, future studies may consider a sequential application of the therapeutics, to circumvent the adverse effects observed during simultaneous treatment. Thus, the advantages of both pro‐anabolic and antioxidative therapy could be harnessed. As NAC has been shown to potently attenuate early trauma‐induced processes, it might be advisable to initiate the therapy with the antioxidative approach. To achieve optimal efficacy of NAC, it may be administered for about 7 days [14](#jcmm13295-bib-0014){ref-type="ref"}, [15](#jcmm13295-bib-0015){ref-type="ref"}. After primary harm reduction by NAC, pro‐anabolic stimulation of the surviving chondrocytes towards ECM‐regeneration may follow. Previous findings suggest that therapeutic effects on cell viability and suppression of MMP‐13 secretion might be sustained for at least another week after deprivation of NAC [14](#jcmm13295-bib-0014){ref-type="ref"}. Nevertheless, our data indicate that this does not apply to the inhibition of gene expression and biosynthesis of type II collagen, which in fact exhibited significant recovery after deprivation of NAC. Likewise, NAC‐induced gene expression of COL10A1 has been vanished after withdrawal of the antioxidant. Finally, the effect of growth factor‐based chondroanabolic treatment in a sequential setting after antioxidative therapy and its optimal timing is not known at present and clearly deserves further investigation.
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